BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People’s Republic of China, the United States, and internationally. More Details
Excellent balance sheet with limited growth.
Share Price & News
How has BeiGene's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BGNE's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BGNE exceeded the US Biotechs industry which returned 31.3% over the past year.
Return vs Market: BGNE exceeded the US Market which returned 12.7% over the past year.
Price Volatility Vs. Market
How volatile is BeiGene's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StDid You Miss BeiGene's (NASDAQ:BGNE) Impressive 194% Share Price Gain?
1 month ago | Simply Wall StHere's What BeiGene, Ltd.'s (NASDAQ:BGNE) Shareholder Ownership Structure Looks Like
2 months ago | Simply Wall StHow Much Is BeiGene's (NASDAQ:BGNE) CEO Getting Paid?
Is BeiGene undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: BGNE ($268.8) is trading above our estimate of fair value ($134.47)
Significantly Below Fair Value: BGNE is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BGNE is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: BGNE is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BGNE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BGNE is overvalued based on its PB Ratio (8.3x) compared to the US Biotechs industry average (3.4x).
How is BeiGene forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BGNE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BGNE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BGNE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BGNE's revenue (47.8% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: BGNE's revenue (47.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BGNE is forecast to be unprofitable in 3 years.
How has BeiGene performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BGNE is currently unprofitable.
Growing Profit Margin: BGNE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BGNE is unprofitable, and losses have increased over the past 5 years at a rate of 61.1% per year.
Accelerating Growth: Unable to compare BGNE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BGNE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: BGNE has a negative Return on Equity (-54.89%), as it is currently unprofitable.
How is BeiGene's financial position?
Financial Position Analysis
Short Term Liabilities: BGNE's short term assets ($3.4B) exceed its short term liabilities ($551.2M).
Long Term Liabilities: BGNE's short term assets ($3.4B) exceed its long term liabilities ($805.6M).
Debt to Equity History and Analysis
Debt Level: BGNE's debt to equity ratio (12.5%) is considered satisfactory.
Reducing Debt: BGNE's debt to equity ratio has reduced from 12.9% to 12.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BGNE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BGNE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is BeiGene current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BGNE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BGNE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BGNE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BGNE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BGNE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Oyler (52 yo)
Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009. ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD12.58M) is about average for companies of similar size in the US market ($USD11.33M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
|GM of China & President||2.33yrs||US$9.13m||0.031% |
|CFO & Chief Strategy Officer||5.17yrs||US$4.19m||0.0025% |
|Chief Medical Officer of Hematology||4yrs||US$3.61m||0.014% |
|Vice President of Finance & Accounting||no data||no data||no data|
|Senior Director of Investor Relations||no data||no data||no data|
|Senior VP & General Counsel||no data||no data||no data|
|VP and Global Head of Quality & Regulatory Compliance||3.25yrs||no data||no data|
|Head of Discovery Biology & Senior VP||9.92yrs||no data||no data|
|Acting Head of Medicinal Chemistry||no data||no data||no data|
|Head of Molecular Sciences and Senior Vice President||4yrs||no data||no data|
Experienced Management: BGNE's management team is considered experienced (4.6 years average tenure).
|Independent Non-Executive Director & Member of the Scientific Advisory Committee||0.58yr||US$372.47k||0.034% |
|Independent Non-Executive Director & Member of the Scientific Advisory Committee||0.58yr||US$354.97k||0.00079% |
|Independent Non-Executive Director||7.58yrs||US$362.47k||0.30% |
|Director & Member of Scientific Advisory Committee||0.083yr||no data||no data|
|Non Executive Director & Chairman of the Commercial Advisory Committee||0.58yr||no data||no data|
|Independent Non-Executive Director & Member of the Commercial Advisory Committee||0.58yr||US$356.64k||0% |
|Independent Non-Executive Director & Member of the Commercial Advisory Committee||4.58yrs||US$367.47k||0% |
|Independent Lead Director & Member of the Commercial Advisory Committee||0.58yr||US$357.47k||0.00079% |
|Independent Non-Executive Director & Member of the Scientific Advisory Committee||5.92yrs||US$370.80k||0% |
Experienced Board: BGNE's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BGNE insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49.2%.
BeiGene, Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: BeiGene, Ltd.
- Ticker: BGNE
- Exchange: NasdaqGS
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$24.298b
- Shares outstanding: 90.40m
- Website: https://www.beigene.com
Number of Employees
- BeiGene, Ltd.
- No.30 Science Park Road
- Zhong-Guan-Cun Life Science Park
- Beijing Province
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BGNE||NasdaqGS (Nasdaq Global Select)||Yes||SPON ADS EACH REPR 13 ORD||US||USD||Feb 2016|
|49BA||DB (Deutsche Boerse AG)||Yes||SPON ADS EACH REPR 13 ORD||DE||EUR||Feb 2016|
|BGNE N||BMV (Bolsa Mexicana de Valores)||Yes||SPON ADS EACH REPR 13 ORD||MX||MXN||Feb 2016|
|49B||DB (Deutsche Boerse AG)||Ordinary Shares||DE||EUR||Aug 2018|
|6160||SEHK (The Stock Exchange of Hong Kong Ltd.)||Ordinary Shares||HK||HKD||Aug 2018|
|6160||SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect)||Ordinary Shares||HK||HKD||Aug 2018|
|6160||SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)||Ordinary Shares||HK||HKD||Aug 2018|
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People’s Republic of China, the United States, and i ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/23 06:10|
|End of Day Share Price||2020/09/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.